SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

GLD is trending as investors discuss gold's safe-haven appeal amid dollar concerns and potential bond market issues. The community is debating whether the rally is sustainable, with some predicting further gains while others foresee a significant correction. Broader economic factors, including U.S.-China trade dynamics and potential Federal Reserve actions, are also fueling the conversation.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending downwards as the community debates whether it's a scam or a buying opportunity, with some pointing to the CEO's past sale of shares as a negative signal. Discussions include potential price targets, upcoming earnings, and the overall valuation of the quantum computing sector. Bears anticipate a significant drop, while bulls hope for a rebound, contributing to the stock's volatility.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid concerns about regional banks and a potential trade war with China, leading to market jitters. The community is actively discussing potential support levels and hedging strategies, with some anticipating a market crash while others foresee a bounce. Gold's surge to record highs is also fueling debate about market stability and potential investment shifts.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices surge, driven by a potential short squeeze and heightened demand. Community discussions revolve around the possibility of triple-digit silver prices and the impact of a weaker dollar, while some caution against an overbought market and potential pullbacks. The broader context includes concerns about regional bank instability and a flight to safety in precious metals.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is trending due to a potential breakout and renewed bullish sentiment, with the index reaching new all-time highs. Community members are actively discussing the potential for small caps to outperform and some expect the rally to continue, while others caution about overbought conditions and potential pullbacks amid macro uncertainty.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending amid discussions about potential acquisitions and expansion plans, including a possible move into stablecoins and new crypto listings; the community is analyzing technical patterns and speculating on future price movements, while also keeping an eye on Bitcoin's influence and overall market conditions.

SharpLink Gaming, Inc. is an online performance-based marketing company, which engages in the provision of online platform facilitating sports betting. It connects sports fans, leagues, and sports websites to relevant and timely sports betting content. The company was founded by Robert Phythian in 2019 and is headquartered in Minneapolis, MN.

SharpLink Gaming Inc.

SharpLink Gaming Ltd

SBET is trending due to a recently priced share offering at a premium, signaling institutional confidence and sparking community discussion about the company's Ethereum strategy. Some investors are excited about the potential for future gains as the company continues to accumulate ETH, while others express concerns about dilution and management's performance relative to peers like BMNR. The stock's movements are closely tied to Ethereum's price, making it a subject of debate as crypto markets experience volatility.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is seeing increased volatility as traders weigh geopolitical concerns, banking sector jitters, and potential impacts from upcoming economic reports. Community members are actively discussing potential downside risks and hedging strategies, while also debating whether the current market dip presents a buying opportunity or signals a larger correction.

Bitfarms Ltd. (Canada) engages in the business of mining cryptocurrency. The firm is also involved in the ownership and operation of server farms comprised of computers designed for the purpose of validating transactions on the Bitcoin blockchain. The company was founded by Emiliano Joel Grodzki and Nicolas Bonta in 2017 and is headquartered in Toronto, Canada.

Bitfarms Ltd.

BITF is trending due to news of a $500M convertible note offering, increased from an initial $300M, causing mixed reactions among investors. While some fear dilution and a price drop, others view it as a necessary step for funding operations and AI development. The community is actively debating the offering's impact and management's trustworthiness, with some looking ahead to a Monday space talk for further details.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as discussions revolve around its AI and Azure divisions, with analysts predicting significant revenue growth and strong performance. Community members are actively trading MSFT, using Elliott Wave analysis to identify buying opportunities and potential price extensions. Bullish sentiment is fueled by Azure's growth outpacing rivals and excitement around Copilot and OpenAI integrations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MindMed Announces New Employee Inducement Grant

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the Company or MindMed), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year?

Here is how ANIXA BIOSCIENCES INC (ANIX) and Mind Medicine (MindMed) Inc. (MNMD) have performed compared to their sector so far this year.

All You Need to Know About Mind Medicine MindMed (MNMD) Rating Upgrade to Buy

Mind Medicine MindMed (MNMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to Trade

Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect?

Shares of Mind Medicine Inc. climbed 3.6% on Thursday and extended gains after hours, with retail sentiment improving following the company's fourth-quarter earnings report.The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier, largely due to higher research and development costs tied to its MM120 and MM402 programs.&nbsp;MM120, MindMed's lead drug candidate, is designed to treat generalized anxiety disorder (GAD), while MM402 is being developed to address core symptoms of Autism Spectrum Disorder (ASD).However, the company's adjusted Q4 loss per share of $0.41 narrowed from $0.59 a year ago, though it missed analyst expectations of a $0.28 loss.CEO Rob Barrow remained upbeat, stating that 2024 was a "year of significant progress" and that the company had achieved key milestones leading into multiple Phase 3 clinical readouts for MM120, which he expects to drive MindMed's next growth phase.On Stocktwits, sentiment for MNMD shifted from 'bearish' to 'neutral' in the 24 hours leading up to Thursday, with message volume surging 250%.<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MNMD_sentiment_and_message_volume_as_of_March_6_8b8a5ebcbf.png" alt="MNMD sentiment and message volume as of March 6.png" width="1316" height="302"><figcaption>MNMD sentiment and message volume as of March 6 | source: Stocktwits</figcaption></figure>One user expressed confidence in MM120's potential, saying, "Once Phase 3 [of the MM120 study] passes, this is going to blow up."<stembedurl>https://stocktwits.com/Bball4/message/606995440</stembedurl>Another key factor boosting optimism was MindMed's strong cash reserves. The company ended 2024 with $273.7 million in cash and cash equivalents, up from $99.7 million a year earlier, which the company expects to be sufficient to support operations into 2027.One user wrote, "We won't have to do any more reverse splits. MNMD has cash reserves until approvals."<stembedurl>https://stocktwits.com/BullsVSBearsVSYoMomma/message/607108323</stembedurl>Additionally, traders pointed to potential government&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mnmd-stock-soars-after-rfk-jr-confirmed-as-hhs-chief/ch5iJvpRH6">support</a> under new Health and Human Services chief Robert F. Kennedy Jr., who has previously advocated for the decriminalization of psychedelics for therapeutic use.The company also plans regulatory and pre-commercialization activities for MM120's orally disintegrating tablet (ODT) version.One watcher pointed out that although MNMD lags behind competitor Compass Pathways in clinical progress, its broader drug pipeline gives it an edge.Mind Medicine shares remain down over 7% year-to-date but have gained over 10% in the past 12 months.&nbsp;According to Koyfin, of the 11 analysts covering the stock, seven rate it a 'buy,' while four have a 'strong buy' rating.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mind Medicine's Net Losses Swell In Q4, But Retail Finds At Least 3 Reasons To Stay Bullish

The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier.

Equity

The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier.


MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the 'Company' or 'MindMed'), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

Shares of Mind Medicine Inc. (MNMD) surged more than 15% Friday afternoon, on track for their best session since April 2024, as retail traders cheered Robert F. Kennedy Jr.’s confirmation as U.S. Health and Human Services secretary.The stock is now set to post weekly gains of over 22%, its strongest performance since the week of Donald Trump’s 2024 election victory in November.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MNMD_sentiment_Feb_14_dada4484f8.png" alt="MNMD sentiment Feb 14.png" width="1318" height="324"><figcaption>MNMD sentiment Feb 14 as of 2:30 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment turned even more bullish, with message volume skyrocketing 720% in the past three months amid RFK Jr.’s rise to the cabinet.“The RFK bump,” one user wrote, echoing several other posts, while another predicted a “big breakout” next week.&nbsp;<stembedurl>https://stocktwits.com/mpferd/message/604362153</stembedurl><stembedurl>https://stocktwits.com/Knot2/message/604306853</stembedurl>Kennedy has previously&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/livecoverage/trump-cabinet-confirmation-hearings/card/what-has-rfk-jr-said-about-weight-loss-drugs-antidepressants-and-psychedelics--eAaDAxA6vQaSVMeBPlEs">advocated</a> for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.Wall Street has also taken notice.&nbsp;Earlier this month, Chardan named Mind Medicine as a top biotech pick for 2025, citing strong Phase 2 results for its lead drug candidate MM120, which targets generalized anxiety disorder (GAD).&nbsp;The research firm has a ‘Buy’ rating with a $20 price target — implying a doubling from current levels — and projects potential MM120 peak sales of over $1 billion by 2026.In January, Evercore ISI <a href="https://stocktwits.com/news-articles/markets/equity/mnmd-stock-rises-on-evercore-isi-rating/chbVQU4RYM">initiated</a> coverage with an ‘Outperform’ rating and a $23 target, highlighting Mind Medicine’s innovative oral LSD formulation and its potential in treating both GAD and major depressive disorder (MDD).Still, not everyone’s betting on more gains. Short interest has climbed from 12.9% at the start of the year to 14.2% by January’s end, per Koyfin data.<a href="https://stocktwits.com/symbol/MNMD">Mind Medicine shares</a> have gained over 42% year-to-date, outperforming Compass Pathways but lagging Atai Life Sciences’ 79% surge. Those two companies are also developing psychedelic therapeutics.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Robert F. Kennedy Jr. speaks after being sworn in as Secretary of Health and Human Services in the Oval Office at the White House on February 13, 2025 in Washington, DC. (Photo by Andrew Harnik/Getty Images)

Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months

Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the Company or MindMed), a late-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that...

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the 'Company' or 'MindMed'), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Mind Medicine Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$11.91
Prev Close	$12.66
Open	$12.76
Dividend Yield	0.00%
50-Day Moving Average	$10.34
Beta	1.68
Avg. Volume	1.47M
PE Ratio	-8.65

52-Week High	$13.09
52-Week Low	$4.70
Market Capitalization	$956.5M
EPS (Annual)	-$1.54
Price to Book	5.18
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

MNMD
Mind Medicine Inc - Ordinary Shares (Sub Voting)

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MNMD News

MNMDMind Medicine Inc - Ordinary Shares (Sub Voting)